By Dr Peter Carter
GLP‑1 weight‑loss drugs are promoted as life‑changing treatments. They help people lose weight quickly and offer a sense of control that many have not felt before. But is this view too short-termist?
The central issue is durability. These drugs work while people take them, but the benefits can evaporate when treatment stops. Weight commonly returns and sometimes rapidly. If meaningful results depend on taking these medications for the longer term, patients deserve to know that upfront. So, are we advising patients to commit to taking these medications forever? When and how should they be advised to stop? These questions don’t seem resolved.
There’s also a problem of fairness. Access to these drugs is already uneven. People in wealthier areas are more likely to start treatment at lower weights, and those who can afford private care can begin earlier and continue for longer. If the real benefits of these drugs require ongoing use, then inequality shifts from who can start to who can stay on them. Those with fewer resources may be left cycling between brief improvements and rapid relapse.
Meanwhile, the rise of “enhancement” use—people taking the drugs for aesthetic reasons rather than medical need—risks diverting resources from those who face the greatest health burdens and have to be in a worse situation to access them.
None of this means GLP‑1 drugs shouldn’t be used. They offer real help to many, but their benefits depend on long‑term commitment. Access to treatment should be fair and policies should prevent new inequalities from forming.
Author: Dr Peter Carter
Affiliations: School of Medicine, Anglia Ruskin University
Competing interests: None to declare
Social media: @padder1.bsky.social